drugset / Trial / NCT04900818
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Non-randomizedSequentialDouble-blindTreatment
Summary
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Timeline
- Start
- 2021-06-29
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TJ033721 | Unknown | 0.1 mg/kg | — |
| Subject | TJ033721 | Unknown | 0.3 mg/kg | — |
| Subject | TJ033721 | Unknown | 1 mg/kg | — |
| Subject | TJ033721 | Unknown | 3 mg/kg | — |
| Subject | TJ033721 | Unknown | 5 mg/kg | — |
| Subject | TJ033721 | Unknown | 8 mg/kg | — |
| Subject | TJ033721 | Unknown | 12 mg/kg | — |
| Subject | TJ033721 | Unknown | 15 mg/kg | — |
| Subject | TJ033721 | Unknown | 18 mg/kg | — |
| Background | Durvalumab | Monoclonal antibody | — | — |
| Background | Nivolumab | Monoclonal antibody | — | — |